Hematologic Neoplasms clinical trials at University of California Health

3 in progress, 2 open to eligible people

Showing trials for

  • (Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis

    open to eligible people ages 18 years and up

    This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).

    at UCLA

  • Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation in Patients With Hematologic Malignancy

    open to eligible people ages 18 years and up

    The purpose of this study is to investigate whether the combination of cyclophosphamide and abatacept versus the treatment used in standard of care will reduce the incidence of moderate and severe chronic graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation. GVHD occurs when the cells from your donor (the graft) see your body's cells (the host) as different and attack them.

    at UCSD

  • A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

    Sorry, in progress, not accepting new patients

    The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with margetuximab in HER2+ advanced solid tumors. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of tebotelimab will also be assessed.

    at UCLA

Our lead scientists for Hematologic Neoplasms research studies include .

Last updated: